MARKET

VYGR

VYGR

Voyager
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.190
-0.040
-1.24%
Closed 19:47 07/29 EDT
OPEN
3.260
PREV CLOSE
3.230
HIGH
3.300
LOW
3.170
VOLUME
188.31K
TURNOVER
--
52 WEEK HIGH
12.65
52 WEEK LOW
3.040
MARKET CAP
120.35M
P/E (TTM)
3.086
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19)
Benzinga · 07/20 12:19
Stocks That Hit 52-Week Lows On Monday
  Stocks That Hit 52-Week Lows On Monday Monday morning, 285 companies reached new 52-week lows.
Benzinga · 07/19 14:04
Aerovate Therapeutics Appoints Allison Dorval To Its Board of Directors
Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the appointment of Allison Dorval, chief f...
GlobeNewswire · 07/19 12:00
The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 15)
Benzinga · 07/16 11:37
The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8)
Benzinga · 07/09 11:36
The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7)
Benzinga · 07/08 11:45
Stocks That Hit 52-Week Lows On Wednesday
  Before 10 a.m. ET on Wednesday, 49 companies set new 52-week lows.
Benzinga · 07/07 14:01
The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 6)
Benzinga · 07/07 11:41
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VYGR. Analyze the recent business situations of Voyager through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VYGR stock price target is 9.61 with a high estimate of 20.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 180
Institutional Holdings: 30.72M
% Owned: 81.43%
Shares Outstanding: 37.73M
TypeInstitutionsShares
Increased
30
2.64M
New
18
1.50M
Decreased
31
4.76M
Sold Out
16
498.36K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.31%
Key Executives
Chairman/President/Chief Executive Officer/Director
Michael Higgins
Chief Financial Officer/IR Contact Officer
Allison Dorval
Senior Vice President/General Counsel
Robert Hesslein
Chief Scientific Officer/Director
Glenn Pierce
Director
Steven Paul
Independent Director
James Geraghty
Independent Director
Steven Hyman
Independent Director
Mark Levin
Independent Director
Nancy Vitale
No Data
  • All
  • Financials
  • Insiders
More
About VYGR
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company's pipeline consists of programs for CNS indications, including advanced Parkinson's disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington's disease; Friedreich's ataxia; frontotemporal dementia/Alzheimer's disease, and severe chronic pain. The Company's clinical candidate, VY-AADC01, is an adeno-associated virus (AAV) gene therapy product candidate, for the treatment of advanced Parkinson's disease. VY-AADC01 consists of the AAV2 capsid, which has been used in multiple AAV gene therapy clinical trials for various diseases, and the cytomegalovirus promoter that drives expression of the aromatic L-amino acid decarboxylase (AADC) transgene. Its pipeline also includes VY-SOD101, VY-FXN01, VY-HTT01, VY-TAU01 and VY-NAV01.

Webull offers kinds of Voyager Therapeutics Inc stock information, including NASDAQ:VYGR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VYGR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VYGR stock methods without spending real money on the virtual paper trading platform.